Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis.

Literature DB >> 19922731

Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis.

Abstract

In the past several years, significant progress has occurred in the therapeutic management of antineutrophil cytoplasmic antibody-associated vasculitis. This has resulted in improved survival rates for all members of this group of inflammatory vascular disorders. However, the rate of treatment failure or resistance and relapse has remained relatively constant despite therapeutic advances. This article reviews risk factors associated with these failures, with hopes that better understanding may lead to improved therapeutic responses and less therapy-related toxicity.

Entities: Disease

Mesh：

Substances：

Year: 2009 PMID： 19922731 DOI： 10.1007/s11926-009-0061-x

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

47 in total

1. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.

Authors: Herbert A Hauer; Ingeborg M Bajema; Hans C van Houwelingen; Franco Ferrario; Laure-Hélène Noël; Rüdiger Waldherr; David R W Jayne; Niels Rasmussen; Jan A Bruijn; E Christiaan Hagen
Journal: Kidney Int Date: 2002-01 Impact factor: 10.612

Review 2. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis.

Authors: Coen A Stegeman
Journal: Nephrol Dial Transplant Date: 2002-12 Impact factor: 5.992

3. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.

Authors: J-S F Sanders; M G Huitma; C G M Kallenberg; C A Stegeman
Journal: Rheumatology (Oxford) Date: 2006-01-06 Impact factor: 7.580

4. Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis.

Authors: K Zycinska; K A Wardyn; T M Zielonka; U Demkow; M S Traburzynski
Journal: J Physiol Pharmacol Date: 2008-12 Impact factor: 3.011

5. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.

Authors: D Roccatello; S Baldovino; M Alpa; D Rossi; F Napoli; C Naretto; R Cavallo; O Giachino
Journal: Clin Exp Rheumatol Date: 2008 May-Jun Impact factor: 4.473

6. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors: L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal: Arthritis Rheum Date: 1997-12

7. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors: Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal: Arthritis Rheum Date: 2005-01

8. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up.

Authors: Zdenka Hruskova; Zuzana Rihova; Helena Mareckova; Eva Jancova; Romana Rysava; Jakub Zavada; Miroslav Merta; Tomas Löster; Vladimir Tesar
Journal: Arch Med Res Date: 2009-05 Impact factor: 2.235